- Previous Close
2.3500 - Open
2.3950 - Bid 2.4000 x --
- Ask 2.8000 x --
- Day's Range
2.3950 - 2.8000 - 52 Week Range
2.1500 - 9.5000 - Volume
3,264,411 - Avg. Volume
1,510,683 - Market Cap (intraday)
3.529M - Beta (5Y Monthly) -0.31
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Apr 24, 2025 - Apr 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy, toxicology studies, and orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics for solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and natural killer cell-mediated anti-cancer action. The company was incorporated in 2020 and is based in London, the United Kingdom.
www.roquefortplc.comRecent News: ROQ.L
View MorePerformance Overview: ROQ.L
Trailing total returns as of 2/7/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ROQ.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ROQ.L
View MoreValuation Measures
Market Cap
3.53M
Enterprise Value
3.54M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
23.25
Price/Book (mrq)
0.72
Enterprise Value/Revenue
20.56
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-15.86%
Return on Equity (ttm)
-27.05%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-1.54M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
595.66k
Total Debt/Equity (mrq)
12.37%
Levered Free Cash Flow (ttm)
-881.77k